A new publication referencing pasireotide was released on October 13, 2026. The article, titled "Personalised acromegaly treatment: implementing precision medicine in the Gulf States," appeared in Frontiers in Endocrinology. The publication addresses precision medicine approaches in the context of acromegaly care within the Gulf States region. No specific findings, outcomes, or efficacy data from the publication have been provided alongside this announcement. This entry reflects only the existence and bibliographic details of the publication as recorded. Readers interested in the broader context of pasireotide, including its approved regulatory status, can consult the compound overview for further background. The publication is indexed under PubMed ID 42947680 and can be accessed through the associated journal listing.
Pasireotide Featured in New Acromegaly Precision Medicine Publication
See the full pasireotide overview
Source: https://pubmed.ncbi.nlm.nih.gov/42947680/